Finance

Lists
CVS:NYSE
CVS Health Corp
USD 90,85
-0,92%
(-0,84) 1D
17 Sep., 15:14:07 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CVS...
Open
USD 92,00
High
USD 92,14
Low
USD 90,84
Mkt. cap
116,19 mjd
Avg. vol.
7,01 m
Volume
3,19 m
Dividend
2,93%
Quarterly dividend
USD 0,67
Ex-dividend date
23 Apr. 2026
P/E ratio
24,09
52-wk high
USD 110,68
52-wk low
USD 69,51
EPS
USD 3,77
Beta
0,59
Shares outstanding
1,28 mjd
No. of employees
260 k
Open
USD 92,00
High
USD 92,14
Low
USD 90,84
Mkt. cap
116,19 mjd
Avg. vol.
7,01 m
Volume
3,19 m
Dividend
2,93%
Quarterly dividend
USD 0,67
Ex-dividend date
23 Apr. 2026
P/E ratio
24,09
52-wk high
USD 110,68
52-wk low
USD 69,51
EPS
USD 3,77
Beta
0,59
Shares outstanding
1,28 mjd
No. of employees
260 k
News stories
From web sources and news partners
Profile
CVS Health Corporation is an American multinational healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider, among many other brands. The company is the world's second largest healthcare company, behind UnitedHealth Group. In 2023, the company was ranked 64th in the Forbes Global 2000. CVS started in Lowell, Massachusetts by brothers Stanley and Sidney Goldstein and their partner Ralph Hoagland. The name stood for Consumer Value Stores. Wikipedia
About CVS Health Corp
CEODavid Joyner
Employees260 k
Founded1963
HeadquartersWoonsocket, Rhode Island, Verenigde State van Amerika
SectorHealth care provider
Analyst ratings
Based on 19 analysts giving stock ratings to CVS in the past 3 months
Strong buy
Buy
18
Hold
1
Sell
0
12-month forecast
Based on 19 Wall Street analysts offering 12 month price targets for CVS in the last 3 months.
Highest
Current USD 90,85
USD 125,00 (+37,59%)
Average
USD 114,37 (+25,89%)
Lowest
USD 103,00 (+13,37%)
Analyst
Recommendation
Action
Price target
Projected
Date
Stephen Baxter
Wells Fargo
Buy
Maintained
USD 123,00
+35,4%
09/15/2026
Allen Lutz
Bank of America Securities
Buy
Maintained
USD 120,00
+32,1%
09/15/2026
Lance Wilkes
Bernstein
Buy
Reiterated
USD 106,00
+16,7%
09/09/2026
Kevin Caliendo
UBS
Buy
Reiterated
USD 118,00
+29,9%
09/03/2026
Brian Tanquilut
Jefferies
Buy
Maintained
USD 120,00
+32,1%
08/31/2026
Charles Rhyee
TD Cowen
Buy
Maintained
USD 110,00
+21,1%
08/26/2026
Jessica Tassan
Piper Sandler
Buy
Maintained
USD 113,00
+24,4%
08/26/2026
Steven Silver
Argus Research
Buy
Maintained
USD 114,00
+25,5%
08/18/2026
Lisa Gill
J.P. Morgan
Buy
Maintained
USD 118,00
+29,9%
08/12/2026
Erin Wright
Morgan Stanley
Buy
Reiterated
USD 111,00
+22,2%
08/10/2026
Ben Hendrix
RBC Capital
Buy
Maintained
USD 113,00
+24,4%
08/06/2026
Michael Ha
Robert W. Baird
Buy
Maintained
USD 107,00
+17,8%
08/06/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
USD 125,00
+37,6%
08/06/2026
David S Macdonald
Truist Financial
Buy
Reiterated
USD 118,00
+29,9%
08/06/2026
Andrew Mok CFA
Barclays
Buy
Maintained
USD 108,00
+18,9%
08/06/2026
Scott Fidel
Goldman Sachs
Buy
Maintained
USD 116,00
+27,7%
07/27/2026
Ann Hynes
Mizuho Securities
Buy
Maintained
USD 120,00
+32,1%
07/13/2026
Sarah James
Cantor Fitzgerald
Buy
Maintained
USD 110,00
+21,1%
07/07/2026
Rajesh Kumar
HSBC
Hold
Maintained
USD 103,00
+13,4%
07/06/2026
George Hill
Deutsche Bank
Buy
Maintained
USD 92,00
+1,3%
05/07/2026
Courtney Breen
Bernstein
Buy
Maintained
USD 94,00
+3,5%
03/30/2026
Michael Cherny
Leerink Partners
Buy
Reiterated
USD 98,00
+7,9%
03/24/2026
Unknown Analyst
Oppenheimer
Hold
Reiterated
-
-
02/11/2026
Last report
05 Aug. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
USD 2,58 / USD 1,85
+39,36%beat
Revenue / Est. (USD)
105,46 mjd / 100,09 mjd
+5,36%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
102,24 mjd
105,10 mjd
99,85 mjd
105,46 mjd
Cost of goods sold
89,06 mjd
92,13 mjd
84,80 mjd
90,35 mjd
Cost of revenue
89,06 mjd
92,13 mjd
84,80 mjd
90,35 mjd
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10,86 mjd
11,32 mjd
10,93 mjd
11,04 mjd
Operating expense
10,86 mjd
11,32 mjd
10,93 mjd
11,04 mjd
Total operating expenses
99,92 mjd
103,45 mjd
95,73 mjd
101,38 mjd
Operating income
2,32 mjd
1,65 mjd
4,12 mjd
4,07 mjd
Other non operating income
26,00 m
-88,00 m
32,00 m
31,00 m
EBT including unusual items
-3,48 mjd
1,35 mjd
3,94 mjd
3,98 mjd
EBT excluding unusual items
2,19 mjd
1,37 mjd
3,95 mjd
3,99 mjd
Income tax expense
508,00 m
-1,57 mjd
981,00 m
982,00 m
Effective tax rate
-14,59%
-115,88%
24,91%
24,69%
Other operating expenses
-
-
-
-
Net income
-3,98 mjd
2,94 mjd
2,94 mjd
2,98 mjd
Net profit margin
-3,89%
2,80%
2,95%
2,82%
Earnings per share
1,60
1,09
2,57
2,58
Interest and investment income
632,00 m
594,00 m
574,00 m
641,00 m
Interest expense
-784,00 m
-787,00 m
-774,00 m
-757,00 m
Net interest expenses
-152,00 m
-193,00 m
-200,00 m
-116,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
3,45 mjd
2,80 mjd
5,23 mjd
5,20 mjd
Gain or loss from assets sale
-483,00 m
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google-programme